Advisors Asset Management’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$416K Buy
12,660
+6,115
+93% +$658K 0.01% 1120
2026
Q2
$569K Sell
6,545
-3,573
-35% -$216K 0.01% 958
2026
Q1
$408K Sell
10,118
-1,908
-16% -$71.3K 0.01% 1010
2025
Q4
$419K Sell
12,026
-5,189
-30% -$408K 0.01% 1001
2025
Q3
$1.43M Sell
17,215
-1,720
-9% -$124K 0.02% 695
2025
Q2
$1.39M Buy
18,935
+237
+1% +$17.2K 0.02% 672
2025
Q1
$2.14M Buy
18,698
+2,607
+16% +$159K 0.04% 542
2024
Q4
$811K Buy
16,091
+3,430
+27% +$180K 0.01% 798
2024
Q3
$586K Buy
12,661
+2,897
+30% +$103K 0.01% 891
2024
Q2
$317K Buy
9,764
+4,177
+75% +$114K 0.01% 1008
2024
Q1
$141K Buy
5,587
+5,055
+950% +$119K ﹤0.01% 1185
2023
Q4
$17.3K Buy
+532
New +$14.6K ﹤0.01% 1363

Other funds holding CORT

Advisors Asset Management's CORT Position: Q3 2026 in Review

Advisors Asset Management increased its Corcept Therapeutics (CORT) stake by 93% in Q3 2026, buying an estimated $658K and bringing the position to 12,660 shares worth $416K. The position accounts for 0.01% of the portfolio, ranked #1120.

Advisors Asset Management first reported a position in CORT in Q4 2023 and has held it in 12 quarters since. The position peaked at $2.14M in Q1 2025. 497 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Advisors Asset Management held 12,660 shares of Corcept Therapeutics worth $416K as of Q3 2026.
  • Advisors Asset Management bought 6,115 Corcept Therapeutics shares in Q3 2026, an estimated $658K.
  • Corcept Therapeutics made up 0.01% of Advisors Asset Management's portfolio in Q3 2026, its #1120 holding.
  • Advisors Asset Management first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Advisors Asset Management's Corcept Therapeutics position peaked at $2.14M in Q1 2025.
  • 497 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Advisors Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.